pyridoxine has been researched along with Schizophrenia in 23 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins." | 9.12 | Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. ( Babushkin, I; Belmaker, RH; Bersudsky, Y; Levine, J; Osher, Y; Ruderman, V; Sela, BA; Shumaico, O; Stahl, Z, 2006) |
| "A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins." | 5.12 | Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. ( Babushkin, I; Belmaker, RH; Bersudsky, Y; Levine, J; Osher, Y; Ruderman, V; Sela, BA; Shumaico, O; Stahl, Z, 2006) |
| " Pyridoxine (Vitamin B6) in essential for the proper metabolism of various neurotransmitters that are considered relevant to the pathophysiology of depression and/or schizophrenia and it has been reported beneficial in ameliorating depressive symptoms as part of major depression, premenstrual syndrome or 'Chinese restaurant syndrome'." | 5.09 | [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial]. ( Dorfman-Etrog, P; Munitz, H; Shiloh, R; Weizer, N; Weizman, A, 2001) |
| "After reviewing the literature on nicotinic acid in the treatment of schizophrenia, the authors present the results of the Canadian collaborative study." | 5.04 | Nicotinic acid in the treatment of schizophrenias. Practical and theoretical considerations. ( Ban, TA, 1975) |
| ", folate, cobalamin, or pyridoxine) potentiated by maternal dietary deficiency of these cofactors and by pregnancy." | 3.70 | DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders. ( Johnson, WG, 1999) |
| "Pyridoxine has been reported to attenuate the severity of levodopa-induced dyskinesias in patients with Parkinson's disease and it is suggested that pyridoxine supplementation should be considered in psychiatric patients with drug-induced movement disorders including persistent Parkinsonism." | 1.28 | Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. ( Pardeshi, R; Sandyk, R, 1990) |
| "4 years were treated with L-Dopa for a period of eight weeks during which the dosage was increased progressively from an initial level of 300 mg q." | 1.26 | Effects of L-dopa and vitamin B6 on electroencephalograms of schizophrenic patients: a preliminary report. ( Yamauchi, M, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (73.91) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y | 1 |
| Li, M | 1 |
| Luo, J | 1 |
| Yang, Y | 1 |
| Li, Z | 1 |
| Li, Y | 1 |
| Zheng, Z | 1 |
| MORRONI, OB | 1 |
| VERGA, G | 1 |
| Levine, J | 1 |
| Stahl, Z | 1 |
| Sela, BA | 1 |
| Ruderman, V | 1 |
| Shumaico, O | 1 |
| Babushkin, I | 1 |
| Osher, Y | 1 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 1 |
| Petrie, WM | 1 |
| Ban, TA | 4 |
| Ananth, JV | 2 |
| Johnson, WG | 1 |
| Shiloh, R | 1 |
| Weizman, A | 1 |
| Weizer, N | 1 |
| Dorfman-Etrog, P | 1 |
| Munitz, H | 1 |
| Lerner, V | 1 |
| Miodownik, C | 1 |
| Kaptsan, A | 1 |
| Cohen, H | 1 |
| Matar, M | 1 |
| Loewenthal, U | 1 |
| Kotler, M | 1 |
| Siva Sankar, DV | 1 |
| Dickerson, JW | 1 |
| Wiryanti, J | 1 |
| Gillin, JC | 1 |
| Kaplan, JA | 1 |
| Wyatt, RJ | 1 |
| Kai, Y | 1 |
| Yamauchi, M | 1 |
| Sandyk, R | 1 |
| Pardeshi, R | 1 |
| Lehmann, HE | 1 |
| Kanig, K | 1 |
| Oesterle, W | 1 |
| Bucci, L | 1 |
| Bowers, MB | 1 |
| Pauling, L | 1 |
| Hollister, LE | 1 |
| Moore, FF | 1 |
| Forrest, F | 1 |
| Bennett, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia[NCT03287778] | 17 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyridoxine and Schizophrenia
| Article | Year |
|---|---|
[PYRIDOXINE IN THE PATHOGENESIS AND THERAPY OF NEUROLOGIC AND PSYCHIATRIC DISEASES].
Topics: Alcoholism; Brain Diseases; Chorea; Extrapyramidal Tracts; Genetics, Medical; Humans; Intellectual D | 1963 |
[Biochemical treatment possibilities in psychoses].
Topics: Amino Acids; Ascorbic Acid; Dihydroxyphenylalanine; Humans; Methionine; Niacinamide; Nicotinic Acids | 1969 |
8 trials available for pyridoxine and Schizophrenia
| Article | Year |
|---|---|
Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Folic Acid; Homocysteine; H | 2006 |
The use of nicotinic acid and pyridoxine in the treatment of schizophrenia.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1981 |
[Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, | 2001 |
Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Hospitalizat | 2001 |
Nicotinic acid in the treatment of schizophrenias. Practical and theoretical considerations.
Topics: Adrenochrome; Antipsychotic Agents; Ascorbic Acid; Clinical Trials as Topic; Drug Evaluation; Drug T | 1975 |
Clinical effects of tryptophan in chronic schizophrenic patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Humans; Male; Placebos; Pyridoxin | 1976 |
Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics.
Topics: Adult; Aminobutyrates; Antipsychotic Agents; Canada; Clinical Trials as Topic; Drug Synergism; Femal | 1973 |
Negative findings with nicotinic acid in the treatment of schizophrenias.
Topics: Adrenochrome; Bufotenin; Dimethoxyphenylethylamine; Drug Therapy, Combination; Female; Humans; Male; | 1974 |
13 other studies available for pyridoxine and Schizophrenia
| Article | Year |
|---|---|
Pyridoxine for the treatment of quetiapine-induced hyperprolactinemia and amenorrhea: A case report.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Drug Administration Schedule; Drug Combinations; Female; Hu | 2019 |
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor | 1963 |
DNA polymorphism-diet-cofactor-development hypothesis and the gene-teratogen model for schizophrenia and other developmental disorders.
Topics: Alleles; Brain; Diet; Female; Folic Acid; Folic Acid Deficiency; Genetic Linkage; Genotype; Humans; | 1999 |
Plasma levels of folates, riboflavin, vitamin B6, and ascorbate in severely disturbed children.
Topics: Adolescent; Affective Symptoms; Ascorbic Acid; Autistic Disorder; Child; Child Behavior Disorders; C | 1979 |
Pellagra and mental disturbance.
Topics: Animals; Brain; Diet; Hartnup Disease; Humans; Mental Disorders; Nicotinic Acids; Pellagra; Pyridoxi | 1978 |
The effect of L-dopa and vitamin B6 in schizophrenia.
Topics: Adult; Alpha Rhythm; Chronic Disease; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mid | 1976 |
Effects of L-dopa and vitamin B6 on electroencephalograms of schizophrenic patients: a preliminary report.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Pyridoxine; Schizophr | 1976 |
Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient.
Topics: Adult; Dyskinesia, Drug-Induced; Humans; Male; Parkinson Disease, Secondary; Pyridoxine; Schizophren | 1990 |
Megavitamin and orthomolecular therapy in psychiatry.
Topics: Aged; Alcoholism; Ascorbic Acid; Avitaminosis; Child; Dose-Response Relationship, Drug; Evaluation S | 1974 |
Pyridoxine and schizophrenia.
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Pilot Projects; Pyridoxine; Schizophrenia | 1973 |
Cerebrospinal fluid 5-hydroxyindoles and behavior after L-tryptophan and pyridoxine adminstration to psychiatric patients.
Topics: Adolescent; Adult; Behavior; Depression; Female; Humans; Indoles; Male; Middle Aged; Psychological T | 1970 |
Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease.
Topics: Aminobenzoates; Biological Evolution; Blood-Brain Barrier; Brain; Brain Diseases; Culture Media; Die | 1968 |
Antipyridoxine effect of D-penicillamine in schizophrenic men.
Topics: Adult; Ceruloplasmin; Copper; Fluorometry; Humans; Male; Middle Aged; Penicillamine; Pyridoxine; Sch | 1966 |